Uniqure NV
QURE13.634USD
-0.061-0.44%
交易中 （美東）報價延遲15分鐘
748.06M總市值
虧損本益比TTM
關於 Uniqure NV 公司
Uniqure NV 是一家總部位於荷蘭的基因治療公司。該公司致力於開發一次性給藥的治療方法，爲患有遺傳性疾病和其他毀滅性疾病的患者提供潛在的治癒效果。該公司通過內部和合作夥伴開發了一系列基因療法。該公司在自己的工廠中生產基於腺相關病毒（或 AAV）的基因療法，採用專有的、商業規模的、符合現行良好生產規範的製造工藝。AMT-061 是該公司針對血友病 B 患者的主要候選產品，目前正在進行關鍵研究的給藥階段。AMT-130 是針對亨廷頓氏病患者的候選產品，目前正處於 I/II 期臨牀研究階段。
公司簡介
公司代碼QURE
公司名稱Uniqure NV
上市日期Feb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
員工數量209
證券類型Ordinary Share
年結日Feb 05
公司地址Paasheuvelweg 25a
城市AMSTERDAM
上市交易所NASDAQ Global Select Consolidated
國家Netherlands
郵編1105 BP
電話31202406000
網址https://www.uniqure.com/
公司代碼QURE
上市日期Feb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+40.66%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-22.96%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月2日 週三
更新時間: 7月2日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Vestal Point Capital, LP
8.73%
RTW Investments L.P.
7.77%
EcoR1 Capital, LLC
7.27%
Nantahala Capital Management, LLC
5.02%
abrdn Inc.
5.01%
Other
66.18%
持股股東
持股股東
佔比
Vestal Point Capital, LP
8.73%
RTW Investments L.P.
7.77%
EcoR1 Capital, LLC
7.27%
Nantahala Capital Management, LLC
5.02%
abrdn Inc.
5.01%
Other
66.18%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
47.15%
Hedge Fund
23.24%
Investment Advisor
15.35%
Corporation
4.36%
Research Firm
3.09%
Venture Capital
2.58%
Individual Investor
1.72%
Private Equity
0.84%
Bank and Trust
0.06%
Other
1.60%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
394
54.93M
100.44%
-2.00M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
2023Q2
452
41.43M
87.10%
-18.53M
2023Q1
454
47.06M
99.04%
-12.29M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Vestal Point Capital, LP
4.79M
8.75%
+1.77M
+58.43%
Mar 31, 2025
RTW Investments L.P.
4.27M
7.79%
+3.36M
+372.04%
Mar 31, 2025
EcoR1 Capital, LLC
3.99M
7.29%
+588.97K
+17.32%
Mar 31, 2025
Nantahala Capital Management, LLC
2.76M
5.03%
+302.60K
+12.33%
Mar 31, 2025
abrdn Inc.
2.22M
4.05%
+706.22K
+46.79%
Mar 31, 2025
Bristol Myers Squibb
2.39M
4.36%
--
--
Sep 30, 2024
Avoro Capital Advisors LLC
2.17M
3.97%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.99M
3.63%
--
--
Mar 31, 2025
Two Sigma Investments, LP
1.58M
2.9%
-50.79K
-3.10%
Mar 31, 2025
683 Capital Management LLC
1.55M
2.83%
+25.00K
+1.64%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco Dorsey Wright Healthcare Momentum ETF
1.53%
WisdomTree BioRevolution Fund
1.09%
Global X Genomics & Biotechnology ETF
0.88%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Main Thematic Innovation ETF
0.46%
Invesco NASDAQ Future Gen 200 ETF
0.43%
SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
查看更多
Invesco Dorsey Wright Healthcare Momentum ETF
佔比1.53%
WisdomTree BioRevolution Fund
佔比1.09%
Global X Genomics & Biotechnology ETF
佔比0.88%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.78%
Main Thematic Innovation ETF
佔比0.46%
Invesco NASDAQ Future Gen 200 ETF
佔比0.43%
SPDR S&P Biotech ETF
佔比0.24%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.14%
Invesco Nasdaq Biotechnology ETF
佔比0.09%
ProShares Ultra Nasdaq Biotechnology
佔比0.09%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
